PHARMACY

Regeneron names new SVP portfolio management

BY David Salazar
TARRYTOWN, N.Y. — Regeneron Pharmaceuticals announced Wednesday the addition of Dr. Jay Markowitz to its leadership team as its new SVP portfolio management. He joins the pharma company from Capital World Investors, where was a U.S. pharmaceutical and biotechnology analyst and portfolio manager. 
 
“Jay is a powerful addition to our leadership team at a very important time for the company as our pipeline continues to grow and diversify," Regeneron president and chief scientific officer Dr. George Yancopoulos said. “Jay's deep scientific and medical expertise, coupled with his incredible track record as a leading biopharma portfolio manager and analyst, will help Regeneron further refine our portfolio strategy in order to bring important new medicines to patients as quickly and efficiently as possible."
 
Markowitz will work with other scientific and development leaders to evaluate the company’s portfolio evaluation and decision making while assessing external opportunities. Before Capital World Investors, Markowitz was a biotechnology analyst and portfolio manager at T. Rowe Price. Before his investment career, he was an assistant professor and transplant surgeon at Johns Hopkins University School of Medicine. 
 
"Regeneron stands out as a company with a robust, diverse pipeline and a deep productive scientific and technological engine," Markowitz said. "I am thrilled to join this great team that is advancing important and promising potential treatments for people with a number of serious diseases."
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Sanofi announces U.S. availability of Soliqua 100/33

BY David Salazar
PARIS — Sanofi on Wednesday announced the U.S. availability of its Soliqua 100/33  (insulin glargine 100 units/mL and lixisenatide 33 mcg/mL) injection pen. The drug, approved by the Food and Drug Administration in November, is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 
 
Sanofi said the daily wholesale acquisition price of Soliqua 100/33 was $127 for a 300 mL pen, an average of about $19.90 per day given the average final dose of 47 mL used in clinical trials. It is also offering it at a $0 for eligible patients with commercial insurance and is working on securing coverage on nationwide health plans. It will also offer Soliqua 100/33 COACH, for patients who have been prescribed the medication. 
 
“By offering Soliqua 100/33 – a product containing both a basal insulin and a GLP-1 therapy — at a competitive price while facilitating patient access, we believe we are providing value to patients and the healthcare system,” Sanofi EVP and head of its global diabetes and cardiovascular business unit Peter Guenter said. 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Genoa acquires Advanced Pharmacy Solutions

BY David Salazar
TUKWILA, Wash. — Genoa is starting its year off by expanding its footprint, announcing Wednesday the acquisition of Mississippi-based Advanced Pharmacy Solutions. With the acquisition, Genoa’s will enter Miss., Tenn., Ark., and S.C., serving 50 additional clinics with its approach to behavioral health that integrates the pharmacists into a patient’s care team in an effort to improve outcomes and reduce costs. 
 
“Genoa and APS share a common mission of improving the lives of individuals living with mental illness, while providing solutions to our clinic partners who serve them,” Genoa CEO John Figueroa said. “This addition allows us to combine our expertise and best practices to better serve consumers and our partner mental health centers. We look forward to bringing even more value and innovative solutions to our partners and consumers.”
 
The companies said the combination is a good fit, given their shared goals of providing high-touch care to patients. 
 
“Over the past seven years APS has worked to build a team that is passionate about and committed to serving the unique needs of patients with mental illness, Community Mental Health Centers, and behavioral health hospitals,” APS CEO Mark Bradford said. “During that time we've grown from caring for a few hundred patients in Mississippi to several thousand patients throughout the Mid-South and Southeast. We're pleased to be partnering with Genoa. Our core values are in alignment, and we share the same passion and commitment to patient care and client service.  We're particularly excited to know our employees, patients, and clients will have access to more resources and cutting edge technology than ever before.”
 
The news comes following the recent publication of a study of patients at Community Mental Health Centers with Genoa’s onsite pharmacy that was published in the November 2016 edition of The Journal of Managed Care & Specialty Pharmacy. The study found higher adherence rates and lower rates of hospitalization related to behavioral health and emergency department visits among those patients whose CMHC used a Genoa pharmacy, when compared to patients at a community pharmacy. 
 
“This peer-reviewed study validates Genoa's positive impact on patients' lives and reflects our team's commitment to working with our community mental health center partners to improve outcomes and reduce healthcare costs,” Figueroa said. “The APS acquisition allows Genoa to expand our reach to help more of the over 40 million Americans with mental illness.”
 
Financial terms of the acquisition were not disclosed. 
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES